DOCKET NO.: JANS-0084(JAB1747USPCT) Application No.: 10/524,123 Office Action Dated: October 11, 2007

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound according to the general Formula (I)

$$(R^1)_{h} \xrightarrow{B} a (CH_2)_m Pir \longrightarrow R^3$$

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, or the N-oxide form thereof, wherein:

- X is CH₂ N-R⁷, S or O;
- R⁷ is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, alkylcarbonyl, alkyloxycarbonyl and mono- and dialkylaminocarbonyl;
- B is a radical, optionally substituted with r radicals R', according to anyone of Formula (B-a) or (B-b) and fused to the isoxazolinyl moiety by either of the bond pairs (c,d), (d,e) or (e,f)

wherein

Het is an optionally substituted 5- or 6-membered heterocyclic ring, selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, oxadiazolyl and triazolyl;

Page 2 of 10

each R¹ is, independently from each other, selected from the group consisting of hydrogen, hydroxy, amino, nitro, cyano, halo and alkyl and, only when R' is attached to a N-atom, is <u>further m h e r</u>-selected from the group of alkyloxyalkyl,

alkyloxyalkyloxyalkyl, alkyloxycarbonylalkyl, fonnyl, alkylcarbonyl, alkyloxyalkylcarbonyl and mono- and dialkylaminocarbonyl;

is an integer ranging from 0 to 6;

a and b are asymmetric centers;

 $(CH_2)_m$ is a straight hydrocarbon chain of m carbon atoms, m being an integer ranging from 1 to 4;

Pir is a radical according to any one of Formula (IIa), (IIb) or (IIc)

$$(a) \qquad (b) \qquad (c)$$

optionally substituted with n radicals R8, wherein:

each R^8 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo and alkyl;

n is an integer ranging from 0 to 5;

R⁹ is selected from the group consisting of hydrogen, alkyl and formyl;

R³ represents an optionally substituted aromatic homocyclic or heterocyclic ring system together with an optionally substituted and partially or completely hydrogenated hydrocarbon chain of 1 to 6 atoms long with which said ring system is attached to the Pir radical and of which may contain one or more heteroatoms selected from the group of O, N and S;

Ar is phenyl or naphthyl, optionally substituted with one or more halo, cyano, oxo, hydroxy, alkyl, formyl, alkyloxy or amino radicals; and

- alkyl represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals.
- (Currently Amended) The compound according to claim 1, wherein R³ is a radical according to any one of Formula (IIIa), (IIIb) or (IIIc)

(a) wherein:

d is a single bond while Z is a bivalent radical selected from the group consisting of -CH₂-, -C(=O)-, -CH(OH)-, -C(=N-OH)-, -CH(alkyl)-, -O-, -S-, -S(=O)-, -NH-and -SH-; or d is a double bond while Z is a trivalent radical of formula =CH- or =C(alkyl)-:

(c)

- A is a 5- or 6-membered aromatic homocyclic or heterocyclic ring, selected from the group consisting of phenyl, pyranyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, oxadiazolyl and isoxazolyl;
- P is an integer ranging from 0 to 6:

(b)

- R⁴ and R⁵ are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, biphenyl, halo and cyano; or
- R⁴ and R⁵ may be taken together to form a bivalent radical -R⁴-R⁵- selected from the group consisting of -CH₂-, =CH-, -CH₂-, -CH=-CH-, -O-, -NH-,

DOCKET NO.: JANS-0084(JAB1747USPCT)
Application No.: 10/524,123
Office Action Dated: October 11, 2007

=N-, -S-,
-CH₂N(-alky1)-, -N(-alky1)CH₂-, -CH₂NH-, -NHCH₂-, -CH=N-, -N=CH-,
-CH₂O- and -OCH₃- ;

each R⁶ is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo, carboxyl, alkyl, Ar, alkyloxy, Ar-oxy, alkylcarbonyloxy, alkyloxycarbonyl, alkylthio, mono- and di(alkyl)amino, alkylcarbonylamino, mono- and di(alkyl)aminocarbonyl, mono- and di(alkyl)arninocarbonyl, mono- and

 $\label{eq:discrete} di(alkyl) aminocarbonyloxy, mono- and di(alkyl) aminoal kyloxy; or \\two vicinal radicals \, R^6 \, may be taken together to form a bivalent radical$

- $-R^6\text{-}R^6\text{-}$ selected from the group consisting of -CH2-CH2-O-, -O-CH2-CH2-,
 - $\hbox{-O-CH$_2$-C(=O)-, -C(=O)-CH$_2$-O-, -O-CH$_2$-O-, -CH$_2$-O-CH$_2$-, -O-CH$_2$-}$
 - CH₂.O-, -CH=CH-CH=CH-, -CH=CH-CH=N-, -CH=CH-N=CH-, -CH=N-CH=CH-, -N=CH-CH=CH-, -CH₂-CH₂-, -CH₂-CH₂-C(=O)-,
- -C(=O)-CH2-CH2, -CH2-C(=O)-CH2-and -CH2-CH2-CH2-CH2 and
- R¹⁶ is selected from the group consisting of hydrogen, alkyl, Ar and Ar-alkyl.
- 3. (Previously Presented) The compound according to claim 2, wherein X = O; m = 1; B is a radical according to Formula (B-a) or (B-b), Pir is a radical according to Formula (IIa) wherein n = 0; R^3 is a radical according to according to any one of Formula (IIIa), (IIIb) or (IIIc) wherein d is a double bond while Z is a trivalent radical of formula =CH- or =C(alkyl)-; A is a phenyl ring; A is hydrogen or alkyl: A and A is a reach hydrogen; A is hydrogen or halo and A is A.
- 4. (Previously Presented) A compound according to claim 1 wherein Het is selected from the group consisting of pyridinyl, thienyl and pyrrolyl, each radical optionally substituted on a N atom with a radical selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkyloxyalkyloxyalkyl, alkyloxyarbonylalkyl, alkyloxycarbonyl, alkyloxycarbonyl and alkyloxyalkylcarbonyl.
- 5. (Previously Presented) A compound which is degraded *in vivo* to yield a compound
 Page 5 of 10

DOCKET NO.: JANS-0084(JAB1747USPCT) Application No.: 10/524,123 Office Action Dated: October 11, 2007

according to claim 1.

6. (Canceled)

7. (Previously Presented) A method of treating a warm-blooded animal suffering from depression, anxiety, movement disorders, psychosis, Parkinson's disease, or body weight disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to said animal.

8. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

(Previously Presented) A process for making a pharmaceutical composition comprising mixing a compound according to claim 1 and a pharmaceutically acceptable carrier.

10. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 and one or more other compounds selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs.

11. (Canceled)

12. (Canceled)

13. (Previously Presented) A process for making a pharmaceutical composition comprising mixing a compound according to claim 1 and a compound selected from the group of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's disease drugs and a pharmaceutically acceptable carrier.